February 2026
LSD
What February 2026's 11 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 5 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research on LSD in February 2026 shows short-term mood improvements from microdosing in depression (Phase 2a trial) and significant antidepressant and anxiolytic effects in a large compassionate-use cohort, but also identifies potential cardiac risks from chronic use via 5-HT2B receptor activation. Results are consistent across clinical and real-world settings, but the evidence is limited by small samples, open-label designs, and lack of long-term safety data.
Confidence in the evidence
Low-Moderate- Only two studies directly address LSD effects: one small Phase 2a trial (microdosing) and one large compassionate-use cohort (full dose), both lacking placebo control.
- The systematic review on cardiac risks includes in vitro and animal data but no human clinical studies on LSD-induced valvulopathy.
- The systematic review on cognitive effects covers multiple psychedelics but notes small samples and difficulty with placebo blinding.
- Evidence is consistent in direction (positive for mood, negative for cardiac risk) but limited in scope and durability.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial 2026 | Phase 2a trial | Supports | Microdosed LSD (8 μg) showed short-term mood improvements with no tolerance or sensitization, warranting further controlled trials. | |
| Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. 2026 | observational (compassionate-use cohort) | 115 | Supports | LSD-assisted psychotherapy (100 μg) significantly reduced depressive and anxiety symptoms with mild, transient adverse events. |
| Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease. 2026 | systematic review | Opposes | LSD has high affinity for 5-HT2B receptors and promotes signaling linked to valvular heart disease in in vitro and structural studies, suggesting potential cardiac risk with chronic use. | |
| Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature 2026 | systematic review | Mixed | LSD and other psychedelics enhanced emotional empathy but impaired reaction time, attention, and inhibition dose-dependently, with mixed effects on memory and cognitive flexibility. | |
| Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI 2026 | RCT (two double-blind, cross-over studies) | 51 | Supports | LSD (100 μg) altered brain connectivity in resting-state networks and limbic regions, with music enhancing these effects, suggesting neural mechanisms for therapeutic outcomes. |
Microdosed LSD (8 μg) showed short-term mood improvements with no tolerance or sensitization, warranting further controlled trials.
Phase 2a trial
LSD-assisted psychotherapy (100 μg) significantly reduced depressive and anxiety symptoms with mild, transient adverse events.
observational (compassionate-use cohort) Sample size: 115
LSD has high affinity for 5-HT2B receptors and promotes signaling linked to valvular heart disease in in vitro and structural studies, suggesting potential cardiac risk with chronic use.
systematic review
LSD and other psychedelics enhanced emotional empathy but impaired reaction time, attention, and inhibition dose-dependently, with mixed effects on memory and cognitive flexibility.
systematic review
LSD (100 μg) altered brain connectivity in resting-state networks and limbic regions, with music enhancing these effects, suggesting neural mechanisms for therapeutic outcomes.
RCT (two double-blind, cross-over studies) Sample size: 51
Points of agreement
- LSD shows acute and short-term positive effects on mood and anxiety in clinical and real-world settings.
- LSD alters brain connectivity and emotional processing, potentially underlying therapeutic benefits.
- Adverse effects are generally mild and transient in controlled settings.
Conflicts
- The systematic review on cognitive effects reports dose-dependent impairments in reaction time and attention, while the clinical studies focus on mood improvements without reporting cognitive deficits.
- Cardiac risk evidence from in vitro studies contrasts with the lack of serious cardiac adverse events in the compassionate-use cohort.
Gaps
- No long-term follow-up data on durability of mood improvements or cardiac safety.
- No placebo-controlled trials for LSD-assisted psychotherapy in the provided studies.
- Limited data on optimal dosing, frequency, and patient selection for LSD therapy.
- No studies on LSD interactions with common medications (e.g., antidepressants) in humans.
- No research on LSD effects in diverse populations or real-world unsupervised use.